Search results for CDKN2A

Anti-Human CDKN2A Polyclonal Antibody, AntibodySystem, PHK35501

Tumor Suppressor ARF (CDKN2A) Antibody, Abbexa, abx125660

CDKN2A Antibody is a Rabbit Polyclonal against CDKN2A.

Anti-CDKN2A/p16INK4a Antibody (R1W26), AntibodySystem, RHE37702

Anti-CDKN2A/p16INK4a Antibody (R1W27), AntibodySystem, RHE37703

Anti-CDKN2A/p16INK4a Antibody (R1W28), AntibodySystem, RME37701

Anti-CDKN2A/p16INK4a Antibody (R1W29), AntibodySystem, RHE37701

CDKN2A Interacting Protein (CDKN2AIP) Antibody, Abbexa, abx002319

CDKN2AIP Antibody is a Rabbit Polyclonal antibody against CDKN2AIP.

HRP Anti-CDKN2A/p14ARF antibody [SP271], Abcam, AB302992

This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This product is FOR RESEARCH USE ONLY. For commercial use, please contact [email protected]. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-CDKN2A/p14ARF antibody [EPR17878], Abcam, AB317910

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

PE Anti-CDKN2A/p14ARF antibody [SP271], Abcam, AB302990

This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This product is FOR RESEARCH USE ONLY. For commercial use, please contact [email protected]. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .